Metastatic clear cell renal cell carcinoma demonstrating intense uptake on $^{68}$Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature

ABSTRACT

$^{68}$Ga-DOTATATE positron emission tomography (PET) is a molecular imaging technology which has shown superiority over $^{111}$In-octreotide scanning for the detection and staging of neuroendocrine tumors. We report three patients with pancreatic masses that were ultimately diagnosed as clear cell renal cell carcinoma (ccRCC) metastases on histopathology. During their initial diagnostic assessment, the three patients underwent both $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) and $^{68}$Ga-DOTATATE PET. While all three patients' lesions showed variable $^{18}$F-FDG avidity, uptake on $^{68}$Ga-DOTATATE PET was comparatively intense. The small case series illustrates the need to consider ccRCC in the differential diagnosis of $^{68}$Ga-DOTATATE avid lesions.

Keywords: $^{68}$Ga-DOTATATE, kidney neoplasms, positron emission tomography, renal cell carcinoma, somatostatin receptors

INTRODUCTION

Clear cell is the most common phenotype of renal cell carcinoma (RCC) and has increased in incidence over recent decades. Current staging investigations are unfortunately less reliable than for many cancer subtypes, with variable uptake and limited sensitivity seen with both $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography (PET)\(^1\) and $^{111}$In-octreotide studies.\(^1,2\) Imaging of carbonic anhydrase IX inhibitor expression has shown potential utility in the diagnosis and prognostication of clear cell RCC (ccRCC);\(^4\) however, its role in clinical management is yet to be fully defined.

CASE REPORTS

Patient one

The first patient was an 86-year-old woman who presented for assessment of central abdominal pain. This occurred in the context of prior RCC, which was in remission following left nephrectomy 15 years prior. Ultrasound examination demonstrated a 3 cm hypervascular mass in the pancreatic body, considered suspicious for a neuroendocrine tumor. An $^{18}$F-FDG and $^{68}$Ga-DOTATATE PET were subsequently performed for characterization and staging. The pancreatic mass showed minimal $^{18}$F-FDG avidity [Figure 1a], however showed comparatively intense uptake on $^{68}$Ga-DOTATATE PET [Figure 1b]. No additional metastatic deposits were seen.

David P. Nadebaum, Sze Ting Lee, Mehrdad Nikfarjam, Andrew M. Scott

1 Department of Molecular Imaging and Therapy, University of Melbourne, Austin Health, 2 Olivia Newton-John Cancer Research Institute, La Trobe University, 3 Department of Surgery, Austin Health, University of Melbourne, Melbourne, Victoria, Australia

Address for correspondence: Dr. David P. Nadebaum, Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia. E-mail: dnadebaum@hotmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Nadebaum DP, Lee ST, Nikfarjam M, Scott AM. Metastatic clear cell renal cell carcinoma demonstrating intense uptake on $^{68}$Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature. World J Nucl Med 2018;17:195-7.
throughout the remainder of the body on either scan. In view of the differential radiotracer uptake, the mass was felt to represent a well-differentiated neuroendocrine tumor. The patient subsequently underwent a central pancreatectomy and retroperitoneal lymph node dissection. Histopathology showed nests of polygonal cells with clear cytoplasms, which stained positive for CD10. The specimen was diagnosed as a ccRCC metastasis rather than a neuroendocrine tumor as initially suspected.

Patient two
The second patient was a 76-year-old man who was diagnosed with a pancreatic lesion during the investigation of abnormal liver function tests. This was on a background of low-grade ccRCC, treated with a partial right nephrectomy 5 years prior. The pancreatic lesion was multifocal, with up to ten rounded enhancing masses seen within the pancreatic body on computed tomography (CT). $^{18}$F-FDG PET showed only mild uptake within the pancreatic mass, in both adrenal glands and the L5 vertebral lamina; the intensity of uptake being considered nondiagnostic and equivocal for malignant disease. In contrast, $^{68}$Ga-DOTATATE PET demonstrated relatively intense uptake throughout all four identified lesions [Figure 2]. A fine needle aspirate of the pancreatic mass subsequently confirmed the diagnosis of recurrent ccRCC.

Patient three
The third patient was an 84-year-old woman who presented after noting a superficial lump overlying her right lower ribs. Diagnostic CT showed a 33 mm subcutaneous mass in the right lower chest wall and multiple pancreatic lesions considered suspicious for metastases. $^{18}$F-FDG PET showed minimal activity in the pancreatic lesion, moderate uptake in the right lower chest wall lesion, and faint uptake in a left infraclavicular lymph node. In contrast, the $^{68}$Ga-DOTATATE PET study showed intense uptake in all of the lesions listed above, as well as additional uptake in a 1 cm pulmonary nodule [Figure 3]. Excisional biopsy of the subcutaneous mass showed rounded epithelial cells with prominent clear cytoplasm that were CD10 positive on immunohistochemistry. Following the diagnosis of metastatic ccRCC, the patient was referred for systemic therapy.

DISCUSSION
We describe a case series of three patients with metastatic ccRCC, who all showed focal uptake on $^{68}$Ga-DOTATATE PET. This finding has had limited description in existing literature, with single case reports of RCC avidity being published for $^{68}$Ga-DOTATATE PET and the related radiotracer $^{68}$Ga-DOTATOC.

While information surrounding $^{68}$Gallium-DOTA-labeled somatostatin analogs in RCC remains limited, the expression of somatostatin receptors (SSTRs) by ccRCC is well recognized. Early investigations by Reubi and Kvols analyzed tissue...
samples from 39 patients with RCC using autoradiography techniques. They not only found SSTR to be expressed in 72% of tumor specimens but also found the receptors to be associated with poor prognosis and metastatic disease. A number of trials have followed, which have assessed the somatostatin analog, octreotide, as both a therapeutic and diagnostic target in ccRCC.

While 111In-pentetreotide has shown some utility as a potential staging tool in ccRCC, the variable octreotide avidity and limited sensitivity have prevented the technique being translated into clinical practice.

68Ga-DOTATATE PET is a more recent molecular imaging technology, which has shown superiority to 111In-pentetreotide scanning for the staging of neuroendocrine tumors. By replacing 111Indium with the positron emitter 68Gallium, 68Ga-DOTATATE PET provides superior imaging characteristics compared to conventional single-photon emission CT. 68Ga-DOTATATE also utilizes octreotide rather than octreotide, an analogous ligand which shows preferential affinity for subtype two of the SSTR2. ccRCC predominantly expresses the SSTR2 receptor subtype, which may further explain the intensity of 68Ga-DOTATATE uptake observed in the above cases.

Our case series provides further reminder that 68Ga-DOTATATE uptake is not pathognomonic of neuroendocrine tumors and that metastatic ccRCC needs to be considered as a differential diagnosis in the appropriate clinical scenario. Histopathologic confirmation significantly influenced the future management of all three patients, which underscores the value of biopsy in the evaluation of 68Ga-DOTATATE avid lesions.

Financial support and sponsorship Nil.

Conflicts of interest There are no conflicts of interest.

REFERENCES

1. Kang DE, White RL Jr., Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:1806-9.
2. Edgren M, Westlin JE, Kälkner KM, Sundin A, Nilsson S. [111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma. Cancer Biother Radiopharm 1999;14:59-64.
3. Montravers F, Rousseau C, Doublet JD, Gattengo B, Allard S, Fouret P, et al. In vivo inaccessibility of somatostatin receptors to 111In-pentetreotide in primary renal cell carcinoma. Nucl Med Commun 1998;19:953-61.
4. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 2007;8:304-10.
5. Kanthan GL, Schembri GP, Samra J, Rouch P, Hsiao E. Metastatic renal cell carcinoma in the thyroid gland and pancreas showing uptake on 68Ga DOTATATE PET/CT scan. Clin Nucl Med 2016;41:583-4.
6. Peter L, Sänger J, Hommann M, Baum RP, Kaemmerer D. Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: A rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med 2014;39:713-6.
7. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992;52:6074-8.
8. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 2000;60:2996-3001.
9. Flamen P, Bossuyt A, De Greve J, Pipeleers-Marichal M, Keuppens F, Somers G. Imaging of renal cell cancer with radiolabelled octreotide. Nucl Med Commun 1993;14:873-7.
10. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012;56:40-7.
11. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 1995;80:2974-9.